Research chemical merchant accounts and the positioning test
SARMs sellers face the same positioning test as peptides but a narrower provider pool. What separates a placeable research supplier from one nobody will board.
Why SARMs & research chemicals gets declined
-
The FDA has issued warning letters over SARMs marketed as dietary supplements or for human use, and acquirers monitor that enforcement feed closely.
-
Positioning decides everything. A research supply business and an unapproved-drug business are distinguished by their marketing, not their inventory.
-
The provider pool is smaller than for peptides, because several acquirers that board peptide suppliers explicitly exclude SARMs.
-
Consumer-facing checkout patterns — residential shipping, quantity guidance, personal-use framing — reclassify the business immediately.
What underwriters actually look for
- Research-use-only positioning carried consistently across the entire domain, including the blog and any affiliate pages.
- Third-party laboratory certificates for every listed product, dated and matched to shipped batches.
- A customer verification step at signup, with institutional and verified-researcher accounts preferred over open consumer checkout.
- Business-address fulfilment and a refusal policy for orders that read as personal use.
- A dispute record you can evidence over six months.
Documents you will be asked for
Having these ready is the single biggest thing that shortens the timeline. The same list is emailed to you after you pre-qualify.
- Government-issued photo ID for each beneficial owner holding 25 percent or more
- Company registration documents and proof of business address
- Three to six months of business bank statements
- Three to six months of processing statements, plus any termination or MATCH notice
- Third-party laboratory certificates for your top-selling products
- Supplier agreements or purchase invoices
- A live link to your checkout, terms and researcher verification step
The same test, a narrower field
If you have read our peptides page, the underwriting test here will be familiar: an analyst opens your website and decides within ninety seconds whether this is a research supply business or an unapproved-drug business with a disclaimer.
What differs is the size of the field. Several acquirers that board research peptides explicitly exclude SARMs, which means fewer providers, less price competition and higher reserves. It also means an approval in one category should never be assumed to carry to the other.
Be specific about what you actually sell. Merchants who describe a mixed catalogue vaguely get underwritten against the hardest item in it.
What fails, in the order it is found
- Quantity or frequency guidance anywhere, including in a blog post from two years ago
- Body-composition, performance or recovery outcomes attached to a product
- Testimonials describing personal use
- Checkout, packaging or shipping options aimed at an individual at home
- Affiliate content making claims you would never make yourself
The fifth is the one that catches careful merchants. Underwriters follow affiliate links, and copy written by a partner is treated as yours.
Before you apply
Fix the domain first. Every application you submit and lose leaves a footprint, and in a category with this few providers you cannot afford to burn one learning what the test was.
What the rules actually say
- SARMs are not approved for human use, and the FDA has acted against products marketed as dietary supplements or for human consumption.
- Research-use-only is a compliance posture rather than a legal exemption. Marketing that implies human use will be read accordingly by both regulators and acquirers.
- Some acquirers that accept research peptides specifically exclude SARMs, so the two categories should not be assumed to travel together.
Jurisdictions we cover
Where your company is established decides which acquiring rails are open to you, and it is one of the five questions we ask up front.
- United States
- United Kingdom
- European Union
- Offshore
Last reviewed
23 August 2026. Regulation in this area moves. Check the primary sources below before acting on anything here, and treat this page as orientation rather than legal advice.
- FDA - warning letters and enforcement actions FDA enforcement activity concerning products marketed for human use without approval.
SARMs & research chemicals: questions merchants ask
Can a SARMs supplier get a merchant account?
Sometimes, and the pool is narrower than for research peptides. What decides it is positioning: research-use-only carried consistently across the whole domain, third-party laboratory certificates, and a verification step at signup. Consumer-facing marketing is declined effectively everywhere.
Is this the same as a peptide application?
The tests are similar but the provider pool is not. Several acquirers that board research peptides explicitly exclude SARMs, so do not assume approval in one category implies the other. It is worth stating clearly which compounds you actually sell.
What gets an application declined fastest?
Human-use framing anywhere on the domain: quantity guidance, body-composition outcomes, personal testimonials, or a checkout designed for an individual buyer at home. Underwriters search the whole indexed domain, not the pages you send them.
What does it cost?
Commonly 5.5 to 9.5 percent plus a per-transaction fee with reserves of 10 to 20 percent held for 180 days. The premium over research peptides is scarcity rather than a different dispute profile.
Do certificates of analysis matter as much here?
Yes. A current third-party certificate per listed product is the baseline document, and being unable to produce one is read as a supply-chain problem rather than a paperwork gap.
Where to go next
Find out what is realistic for sarms & research chemicals
Five questions, no documents, and an honest answer about whether we can place you — including when the answer is no.